CD20 expression by Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma is related to reduced overall survival in young adult patients

Leukemia and Lymphoma

Volumn 49, Issue 11, 2008, Pages 2198-2202

  Aldred, Vera ^a   Vassallo, José ^b,c   Froes M Campos, Antônio Hugo J ^c   Augusto Soares, Fernando ^a,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CD20 ANTIGEN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAZIL; CANCER RELAPSE; CANCER STAGING; CHILD; CLASSICAL HODGKIN LYMPHOMA; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REED STERNBERG CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD20; CHILD; CHILD, PRESCHOOL; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REED-STERNBERG CELLS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 57049086292     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802239170     Document Type: Article

References (14)

1. Isaacson, P. G. and Ashton-Key, M. (1996) Phenotype of Hodgkin's and Reed-Sternberg cells. Lancet, pp. 347-481.
2. Lauritzen, A. F., Moller, P. H., Nedergaard, T., Guldberg, P., Hou-Jensen, K. and Ralfkiaer, E. (1999) Apoptosis-related genes and proteins in Hodgkin's disease. APMIS, 107, pp. 636-644.
3. Vassallo, J., Metze, K., Traina, F., Souza, C. A. and Loran-Metze, I. (2002) Further remarks on the expression of CD20 in classical Hodgkin's lymphomas. Haematologica, 87, p. ELT17.
4. Von Wasielewski, R., Mengel, M., Fisher, R., Hansmann, M. L., Hubner, K. Franklin, J. et al. (1997) Classical Hodgkin's disease. Clinical impact of the immunophenotype. Am J Pathol, 151, pp. 1123-1130.
5. Tzarkov, A., Zimpfer, A., Pehrs, A. C., Lugli, A., Went, P. Mauer, R. et al. (2003) Expression of B-cell markers in classical Hodgkin lymphoma: A tissue microarray analysis of 330 cases. Mod Pathol, 16, pp. 1141-1147.
6. Portlock, C. S., Donnelly, G. B., Qin, J., Straus, D., Yahalom, J. Zelenetz, A. et al. (2004) Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol, 125, pp. 701-708.
7. Rassidakis, G. Z., Medeiros, L. J., Viviani, S., Bonfante, V., Nadali, G. P. Vassilakopoulos, T. P. et al. (2002) CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: Associations with presenting features and clinical outcome. J Clin Oncol, 20, pp. 1278-1287.
8. Tzankov, A., Krugmann, J., Fend, F., Fishhofer, M., Greil, R. and Dirnhofer, S. (2003) Prognostic significance of CD20 expression in classical Hodgkin lymphoma: A clinicopathological study of 119 cases. Clin Cancer Res, 9, pp. 1381-1386.
9. Younes, A., Romaguera, J., Hagemeister, F., McLaughlin, P., Rodriguez, M. A. Fiumara, P. et al. (2003) A pilot study of rituximab in patients with recurrent classic Hodgkin disease. Cancer, 98, pp. 310-314.
10. Kirchner, E. M., Ebsen, M., Kirchner, J., Theegarten, D. and Voigtmann, R. (2001) Transformation of Hodgkin's disease to high-grade B-cell lymphoma: Remission after rituximab monotherapy. Ann Oncol, 12, pp. 1169-1171.
11. Rehwald, U., Schulz, H., Reiser, M., Sieber, M., Staak, J. O. Morschhauser, F. et al. (2003) Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: Results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood, 101, pp. 420-424.
12. Al-Ali, H. K., Wittekind, C. and Niederwieser, D. (2007) Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab. Dtsch Med Wochenschr, 132, pp. 1688-1691.
13. Bai, M. C., Jiwa, N. M., Horstman, A., Vos, W., Kluin, P. H. Van Der Valk, P. et al. (1994) Decreased expression of cellular markers in Epstein-Barr virus positive Hodgkin's disease. J Pathol, 174, pp. 49-55.
14. Keegan, T HMK, Glaser, S. L., Clarke, C. A., Gulley, M. L., Craig, F. E. DiGiuseppe, J. A. et al. (2005) Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: A population-based study. J Clin Oncol, 23, pp. 7604-7613.